Singapore is placing increasing emphasis on artificial intelligence (AI) to transform its healthcare sector, though experts caution that ensuring commercial viability remains a significant challenge. The city-state’s medtech and biotech industries have expanded considerably in recent years, supported by a strong government ecosystem and a deep pool of specialized talent.
Local start-ups such as KroniKare have developed AI-powered solutions like wound care scanners that are now widely used in hospitals across Singapore, reportedly reducing wound assessment times by up to 70 percent. Despite such advancements, only a small fraction of healthcare AI algorithms effectively transition from development to sustainable clinical use, according to Associate Professor Daniel Ting, director of the SingHealth AI Office. Ting highlighted that while innovation is vibrant, the biomedical sciences sector has experienced setbacks in the form of high-profile failures and periods of reduced investor interest, as funding often shifts toward lower-risk industries.
The Singaporean government has made fostering innovation in healthcare a national priority, aligning this goal with the broader National AI Strategy 2.0. This initiative seeks to position the country as a key hub for private sector AI deployment across multiple industries, including healthcare. As part of the Research, Innovation and Enterprise (RIE) 2030 strategy, which allocates $37 billion over five years, the Ministry of Health plans to enhance AI computing capabilities and leverage health data to strengthen medical research capacity. This funding aims to address critical challenges such as the needs of an ageing population.
In July, Singapore launched the Singapore Medical Foundation AI Model, designed to embed AI tools specifically tailored for local patients and medical practices into the public healthcare system. While public and private healthcare providers operate under different models—public care focuses on broad accessibility, whereas private entities pursue profit—Ting noted that both sectors play complementary roles in driving AI adoption and technological transformation.
Private healthcare organisations have increasingly integrated AI across various operations. For example, Fullerton Health employs AI for tasks ranging from analyzing X-rays to coding, while IHH Healthcare, listed on the Singapore Exchange, uses AI to optimize nurse rostering and fee estimation processes. Industry leaders view these operational applications as only the beginning; AI’s potential to revolutionize drug discovery and development is seen as a major growth area.
Ting noted that traditional drug development can take between 10 and 15 years, with high failure rates contributing to elevated costs of medications. Through AI, the process of identifying promising molecules may be accelerated, thereby potentially reducing development timelines and improving productivity. He emphasized that AI is intended to complement rather than replace healthcare workers, characterizing the technology as an augmentative tool designed to assist human efforts rather than supplant them.